



Exploring Hypertensive Cardiotoxicity Among Cancer Patients in Emergency Care Units

Ramling Basling Mali¹, Dr. Berlin Sara Thampy²

¹Research Scholar, Malwanchal University, Indore

²Research Supervisor, Malwanchal University, Indore

Introduction:

Cancer is a prevalent health concern worldwide, affecting millions of individuals annually. With advancements in medical science, the survival rates of cancer patients have increased significantly. However, the treatment modalities employed, such as chemotherapy, radiation therapy, and targeted therapies, come with their own set of complications. One such complication is hypertensive cardiotoxicity, a condition characterized by elevated blood pressure leading to cardiac dysfunction, which poses a significant risk among cancer patients admitted to emergency care units.

This article aims to delve into the intricate relationship between cancer, hypertension, and cardiotoxicity, particularly focusing on its manifestation in emergency care settings. We will explore the mechanisms underlying hypertensive cardiotoxicity, its prevalence among cancer patients, the challenges in diagnosis and management, and strategies for prevention and intervention.

Understanding Hypertensive Cardiotoxicity:

Hypertensive cardiotoxicity refers to the detrimental effects of elevated blood pressure on the heart, leading to structural and functional changes in cardiac tissues. Cancer patients are particularly vulnerable to this condition due to various factors, including the direct effects of tumors, treatment-related complications, and comorbidities such as hypertension and cardiovascular diseases.

Mechanisms:

The pathophysiology of hypertensive cardiotoxicity in cancer patients is multifactorial. Chemotherapeutic agents, such as anthracyclines and tyrosine kinase inhibitors, can induce endothelial dysfunction, oxidative stress, and inflammation, predisposing the heart to hypertensive injury. Additionally, radiation therapy targeting thoracic tumors may cause fibrosis of cardiac tissues and disrupt the autonomic nervous system, contributing to hypertension.

Furthermore, cancer-induced systemic inflammation and neuroendocrine dysregulation can exacerbate hypertension and cardiovascular complications. The activation of the renin-angiotensin-aldosterone system and sympathetic nervous system plays a pivotal role in this process, promoting vasoconstriction and sodium retention, thereby increasing blood pressure and cardiac workload.

Prevalence:

The prevalence of hypertensive cardiotoxicity among cancer patients admitted to emergency care units is significant but often underestimated. Studies have reported varying incidence rates depending on the cancer type, stage, and treatment regimen. For instance, patients receiving high-dose anthracycline therapy or combination chemotherapy are at a higher risk of developing cardiotoxicity.

Diagnosis Challenges:

Diagnosing hypertensive cardiotoxicity in emergency care units can be challenging due to overlapping symptoms with other cardiac conditions and the complexity of cancer-related comorbidities. Common presenting symptoms include chest pain, dyspnea, palpitations, and syncope, which may mimic acute coronary syndrome or heart failure. Moreover, cancer patients often have baseline abnormalities in cardiac biomarkers, making it difficult to interpret test results accurately.

Management Strategies:

The management of hypertensive cardiotoxicity in cancer patients requires a multidisciplinary approach involving oncologists, cardiologists, and emergency care physicians. Prompt recognition and aggressive treatment of hypertension are essential to prevent further cardiac damage and improve patient outcomes. This may involve the use of antihypertensive medications, such as angiotensin-converting enzyme inhibitors, beta-blockers, and calcium channel blockers, tailored to individual patient needs and comorbidities.

In severe cases of hypertensive crisis, intravenous vasodilators like nitroglycerin or nicardipine may be necessary to rapidly lower blood pressure and alleviate symptoms. Close monitoring of cardiac function through serial electrocardiograms, echocardiography, and cardiac biomarkers is crucial for assessing response to treatment and detecting any complications early.

Prevention and Intervention:

Preventing hypertensive cardiotoxicity in cancer patients requires a proactive approach aimed at identifying high-risk individuals and implementing cardioprotective strategies. This includes pre-treatment cardiovascular assessment, optimization of modifiable risk factors such as hypertension and dyslipidemia, and judicious selection of chemotherapeutic agents with lower cardiotoxic profiles whenever possible.

Moreover, lifestyle modifications such as regular exercise, smoking cessation, and adherence to a heart-healthy diet can help mitigate cardiovascular risk in cancer patients. Cardioprotective medications, such as dexrazoxane for anthracycline-induced cardiotoxicity or statins for vascular protection, may also be considered in select cases.

Conclusion:

Hypertensive cardiotoxicity poses a significant threat to cancer patients admitted to emergency care units, necessitating heightened awareness among healthcare providers. By understanding the complex interplay between cancer, hypertension, and cardiac dysfunction, clinicians can optimize the management of these patients and improve their overall prognosis. Through early recognition, aggressive treatment, and targeted interventions, we can mitigate the impact of hypertensive cardiotoxicity and enhance the quality of life for cancer survivors.

In conclusion, addressing the unique cardiovascular challenges faced by cancer patients requires a comprehensive and collaborative approach, integrating oncology and cardiology expertise to deliver personalized care tailored to individual patient needs. Only through such concerted efforts can we effectively mitigate the burden of hypertensive cardiotoxicity and improve outcomes for this vulnerable population.

Reference

1. Siegel R., Mph K.D.M., Jemal A. Cancer statistics, 2018. *CA A Cancer J. Clin.* 2018;68:7–30. doi: 10.3322/caac.21442.
2. Torre L.A., Bray F., Siegel R., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. *CA Cancer J. Clin.* 2015;65:87–108. doi: 10.3322/caac.21262.
3. Maddams J., Utley M., Møller H. Projections of cancer prevalence in the United Kingdom, 2010–2040. *Br. J. Cancer.* 2012;107:1195–1202. doi: 10.1038/bjc.2012.366.
4. Beutner R. The cardiac toxicity of injectable local anesthetics. *Fed. Proc.* 1946;5:166.
5. Chapman D.W., Shaffer C.F. The mercurial diuretics; a comparison of acute cardiac toxicity in animals and the effect of ascorbic acid on detoxification in their intravenous administration. *Proc. Annu. Meet. Cent. Soc. Clin. Res. US.* 1946;19:7.
6. Kyser F.A., Ginsberg H., Gilbert N.C. The effect of certain drugs upon the cardiotoxic lesions of digitalis in the dog. *Am. Heart J.* 1946;31:451–459. doi: 10.1016/0002-8703(46)90427-9
7. Von Hoff D.D., Layard M.W., Basa P. Risk factors for doxorubicin-induced congestive heart failure. *Am. Heart J.* 1979;91:710–717.
8. Chung R., Ghosh A.K., Banerjee A. Cardiotoxicity: Precision medicine with imprecise definitions. *Open Heart.* 2018;5:e000774. doi: 10.1136/openhrt-2018-000774.
9. Guha A., Armanious M., Fradley M.G. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. *Trends Cardiovasc. Med.* 2019;29:29–39. doi: 10.1016/j.tcm.2018.06.001.
10. Iarussi D., Pisacane C., Indolfi P., Casale F., Martino V., Di Tullio M.T. Evaluation of left ventricular function in long-term survivors of childhood Hodgkin disease. *Pediatr. Blood Cancer.* 2005;45:700–705. doi: 10.1002/pbc.20213.
11. Stoddard M.F., Seeger J., Liddell N.E., Hadley T.J., Sullivan D.M., Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. *J. Am. Coll. Cardiol.* 1992;20:62–69. doi: 10.1016/0735-1097(92)90138-D.

-
12. Zhang K.W., Finkelman B.S., Gulati G., Narayan H.K., Upshaw J., Narayan V., Plappert T., Englefield V., Smith A.M., Zhang C., et al. Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction. *JACC Cardiovasc. Imaging*. 2018;11:1059–1068. doi: 10.1016/j.jcmg.2018.01.015.
 13. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: Analysis of worldwide data. *Lancet*. 2005;365:217–223. doi: 10.1016/S0140-6736(05)17741-1.
 14. Piccirillo J.F., Tierney R.M., Costas I., Grove L., Spitznagel E.L., Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. *JAMA*. 2004;291:2441–2447. doi: 10.1001/jama.291.20.2441.
 15. Aggarwal R., Petrie B., Bala W., Chiu N. Mortality Outcomes with Intensive Blood Pressure Targets in Chronic Kidney Disease Patients. *Hypertension*. 2019;73:1275–1282. doi: 10.1161/HYPERTENSIONAHA.119.12697
 16. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., Dai S., Ford E.S., Fox C.S., Franco S., et al. Heart disease and stroke statistics--2014 update: A report from the American Heart Association. *Circulation*. 2014;129:e28–e292. doi: 10.1161/01.cir.0000441139.02102.80.